![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C60H72N8O6 |
Molar mass | 1001.286 g·mol−1 |
3D model ( JSmol) | |
| |
|
Odalasvir ( INN, [1] previously known as ACH-3102) [2] [3] is an investigational new drug in development for the treatment of hepatitis C. [4] It is an NS5A inhibitor. [5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. [6] [7] [8] It is under development by Achillion Pharmaceuticals.[ citation needed]
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C60H72N8O6 |
Molar mass | 1001.286 g·mol−1 |
3D model ( JSmol) | |
| |
|
Odalasvir ( INN, [1] previously known as ACH-3102) [2] [3] is an investigational new drug in development for the treatment of hepatitis C. [4] It is an NS5A inhibitor. [5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. [6] [7] [8] It is under development by Achillion Pharmaceuticals.[ citation needed]